// App-Quantinova.ai

P074 : Time To First Relapse Over The Duration Of Clarity And Clarity Extension In Patients Treated With Cladribine Tablets 3.5 Mg/kg Over Two Years

Researchers

Presenter

  • G. Giovannoni

Principal Investigators

  • G. Pardo

  • A. Ben-Zacharia

  • G. Harty

  • B. Hayward

  • D. L. Jones

  • K. Rammohan

Medical Centers

  • Queen Mary University of London and Blizard Institute Barts and The London School of Medicine and Dentistry London United Kingdom

  • Oklahoma Medical Research Foundation, Oklahoma city, OK.

  • Mount Sinai Medical Center, New York, NY

  • EMD Serono, Inc, Billerica, MA

  • EMD Serono, Rockland, MD

  • Multiple Sclerosis Center, University of Miami, Miami, FL

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Exostosin Glycosyltransferase 1

Drug/Treatment

  • Cladribine

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved